

and Obstetrics, University Hospital of Geneva, Geneva, Switzerland. <sup>13</sup>CANSEARCH research platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland. <sup>14</sup>Department of Oncology, University Children's Hospital, Zurich, Switzerland. <sup>15</sup>Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria. <sup>16</sup>Clinical Cooperation Unit Neuropathology (B<sup>300</sup>), German Cancer Research Center (DKFZ), and German Cancer Consortium (DKTK), Heidelberg, Germany. <sup>17</sup>Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany. <sup>18</sup>Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

**PURPOSE/METHODS:** Clinical and molecular risk factors in 142 patients <5 years with desmoplastic medulloblastoma (DMB) or medulloblastoma with extensive nodularity (MBEN) were investigated. Patients were diagnosed between 1992 and 2020 and treated with radiation-sparing approaches, 131 with intraventricular methotrexate. 14 patients with metastatic disease received high-dose chemotherapy. DNA methylation profiles of 77 somic hedgehog (SHH)-activated medulloblastoma were reclassified according to the Heidelberg Brain Tumor Classifier Version 12.3. **RESULTS:** While metastatic disease or incomplete resection did not impact progression-free survival (PFS) and overall survival (OS), patients with MBEN had superior outcomes to DMB (5-year PFS 93% vs 71%, p=0.004; 5-year OS 100% vs 90%, p=0.026). Older patients had less favorable PFS (5-year PFS >3 years] 47% vs 85% [<1 year] vs 84% [1-3 years], p<0.001). No TP53 mutations were detected (n=47). DNA methylation classification identified three subgroups: SHH-1<sub>v12.3</sub> (n=39), SHH-2<sub>v12.3</sub> (n=19), and SHH-3<sub>v12.3</sub> (n=19), with distinct cytogenetic profiles (chromosome 2 gains in SHH-1<sub>v12.3</sub>, very few alterations in SHH-2<sub>v12.3</sub> and chromosome 9q losses in SHH-3<sub>v12.3</sub>), age profiles (median age [years] SHH-1<sub>v12.3</sub>: 1.7, SHH-2<sub>v12.3</sub>: 0.9, SHH-3<sub>v12.3</sub>: 3.0, p<0.001), and histological distribution (SHH-2<sub>v12.3</sub>: 74% MBEN, SHH-1<sub>v12.3</sub>/SHH-3<sub>v12.3</sub>: 77%/79% DMB, p<0.001). PFS was more unfavorable in patients with SHH-3<sub>v12.3</sub>-medulloblastoma (5-year PFS 53% vs 86% [SHH-1<sub>v12.3</sub>] vs 95% [SHH-2<sub>v12.3</sub>], p=0.002), which remained the only risk factor on multivariable Cox regression for PFS. OS was comparable (5-year OS 94% [SHH-3<sub>v12.3</sub>] vs 97% [SHH-1<sub>v12.3</sub>] vs 100% [SHH-2<sub>v12.3</sub>], p=0.6). 8/9 patients with SHH-3<sub>v12.3</sub>-medulloblastoma received radiotherapy at relapse (6 craniospinal, 2 local [1 Gorlin syndrome, 1 BRCA2 germline mutation], 1 no radiotherapy [Gorlin syndrome]). **CONCLUSION:** We identify patients with an increased risk of relapse when treated with radiation-sparing approaches among children with early childhood SHH-medulloblastoma. If these tumors differ from SHH-3-medulloblastoma typically described in older children remains to be verified. Treatment recommendations need to consider cancer predisposition syndromes.

#### MEDB-42. GERMLINE *ELP1* DEFICIENCY PROMOTES GENOMIC INSTABILITY AND SURVIVAL OF GRANULE NEURON PROGENITORS PRIMED FOR SHH MEDULLOBLASTOMA PATHOGENESIS

Jesus Garcia-Lopez<sup>\*1</sup>, Shiekh Tanveer Ahmad<sup>\*1</sup>, Yiran Li<sup>\*1</sup>, Brian Gudenas<sup>1</sup>, Marija Kojic<sup>2</sup>, Friedrik Manz<sup>3</sup>, Barbara Jonchere<sup>1</sup>, Anand Mayasundari<sup>1</sup>, Aaron Pitre<sup>1</sup>, Jennifer Hadley<sup>1</sup>, Leena Paul<sup>1</sup>, Melissa Batts<sup>1</sup>, Brandon Bianski<sup>1</sup>, Christopher Tinkle<sup>1</sup>, Brent Orr<sup>1</sup>, Zoran Rankovic<sup>1</sup>, Giles Robinson<sup>1</sup>, Martine Roussel<sup>1</sup>, Brandon Wainwright<sup>2</sup>, Lena Kutscher<sup>3</sup>, Hong Lin<sup>#1</sup>, Paul Northcott<sup>#1</sup>; <sup>1</sup>St. Jude Children's Research Hospital, Memphis, TN, USA. <sup>2</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia. <sup>3</sup>Division of Pediatric Neuro-oncology, Heidelberg, Germany

Germline loss-of-function (LOF) mutations in *Elongator complex protein 1* (*ELP1*) are found in 15-20% of childhood SHH medulloblastoma (MB) and are exceedingly rare in non-SHH-MB or other cancers. *ELP1* germline carriers that develop SHH-MB harbor frequent somatic *PTCH1* mutations and universally sustain loss-of-heterozygosity of the remaining *ELP1* allele through chromosome 9q deletion. *ELP1* functions as a scaffolding subunit of the Elongator complex that is required for posttranscriptional modification of tRNAs and maintenance of efficient translational elongation and protein homeostasis. However, the molecular, biochemical, and cellular mechanisms by which *ELP1*/Elongator LOF contribute to SHH-MB tumorigenesis remain largely unknown. Herein, we report that mice harboring germline *Elp1* monoallelic loss (i.e., *Elp1*<sup>+/-</sup>) exhibit hallmark features of malignant predisposition in developing cerebellar granule neuron progenitors (GNPs), the lineage-of-origin for SHH-MB. *Elp1*<sup>+/-</sup> GNPs are characterized by increased replication stress-induced DNA damage, upregulation of the homologous recombination repair pathway, aberrant cell cycle, and attenuation of p53-dependent apoptosis. CRISPR/Cas9-mediated *Elp1* and *Ptc1* gene targeting in mouse GNPs reproduces highly penetrant SHH-MB tumors recapitulating the molecular and phenotypic features of patient tumors. Reactivation of the p53 pathway through MDM2 and PAK4 inhibitors promotes selective cell death in patient-derived xenograft tumors (PDX) harboring deleterious *ELP1* mutations. Together, our findings reveal that germline

*Elp1* deficiency heightens genomic instability and survival in GNPs, providing a mechanistic model for the subgroup-restricted pattern of predisposition and malignancy associated with pathogenic *ELP1* germline carriers. These results provide rationale for further preclinical studies evaluating drugs that overcome p53 pathway inhibition in *ELP1*-associated SHH-MB and a renewed outlook for improving treatment options for affected children and their families. \* , # Contributed equally

#### MEDB-43. DEVELOPMENT OF A BIOINFORMATICS PIPELINE FOR IDENTIFICATION OF DIFFERENTIAL DNA METHYLATION EVENTS ASSOCIATED WITH MEDULLOBLASTOMA RELAPSE

Christopher Kui<sup>1</sup>, Stacey Richardson<sup>1</sup>, Edward C Schwalbe<sup>1,2</sup>, Dean Thompson<sup>1,2</sup>, Claire Keeling<sup>1</sup>, Gordon Strathdee<sup>3</sup>, Christelle Dufour<sup>4</sup>, Simon Bailey<sup>1,5</sup>, Vijay Ramaswamy<sup>6</sup>, Steven C Clifford<sup>1</sup>, Rebecca M Hill<sup>1,5</sup>; <sup>1</sup>Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle-upon-Tyne, United Kingdom. <sup>2</sup>Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle-upon-Tyne, United Kingdom. <sup>3</sup>Biosciences Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle-upon-Tyne, United Kingdom. <sup>4</sup>Department of Pediatric and Adolescent Oncology, Gustave Roussy, <sup>94800</sup>Villejuif, France. <sup>5</sup>Great North Children's Hospital, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom. <sup>6</sup>The Hospital for Sick Children, Toronto, Ontario, Canada

Relapsed medulloblastoma (rMB) is treatment-resistant and fatal in ~95% of cases. The epigenetic features of rMB, and any role as drivers of disease relapse/treatment-resistance have yet to be investigated. We therefore developed a pipeline to identify differentially methylated CpGs (DM-CpGs) and regions (DMRs) in a paired-rMB cohort. Our paired-rMB cohort (n=61, relapsed tumours matched with diagnosis counterparts) with available Illumina Methylation 450K/850K microarray data was processed in *R-Studio*. The packages *Limma* and *DMRcate* were used to perform a paired differential methylation analysis on a filtered selection of array probes (n=335,767), identifying DM-CpGs and DMRs with a 5% FDR. DMRs were further retained if they had a maximum-Δβ of >0.2 and correlated with locus-specific gene expression in a separate paired DNA-methylation array/RNA-seq cohort from medulloblastoma diagnosis samples (n=202). Finally, we created univariable Cox models to assess the prognostic potential of DM-CpGs/DMRs in an independent survival cohort of medulloblastoma diagnosis samples (n=498). Across the paired-rMB cohort, there were few significant differential methylation events initially identified at relapse (n=258 DM-CpGs, n=32 DMRs). Upon sub-analysis by molecular group, MB<sub>Group4</sub> (n=18 pairs) alone yielded significant findings (n=189 DM-CpGs, n=26 DMRs). Most changes involved hypermethylation events detected at relapse. Multiple DM-CpGs identified at relapse were prognostic for both overall and event-free survival when assessed in our independent cohort (n=22 whole cohort, n=13 Group 4, BH-adjusted p<0.05). When applying the DMR filters, only the MB<sub>Group4</sub> DMRs passed the Δβ filter (n=18/26), with few correlating with gene expression (n=2, p<0.001), and none demonstrating prognostic significance. This pipeline facilitates exploration of the clinical relevance of epigenome-wide changes in a paired-rMB cohort. We highlight the potential prognostic significance of DM-CpGs, and future work will explore the potential functional role of candidate-genes associated with our DMRs, as novel drivers of rMB.

#### MEDB-44. TRANSCRIPTOMIC RESOLUTION OF SUBGROUP-SPECIFIC MEDULLOBLASTOMA ARCHITECTURE

Nicholas Willard<sup>1</sup>, Kent Riemondy<sup>2</sup>, Andrea Griesinger<sup>2</sup>, Michael Kaufman<sup>2</sup>, Sujata Venkataraman<sup>2</sup>, Nicholas Foreman<sup>1</sup>, Rajeev Vibhakar<sup>1</sup>, Andrew Donson<sup>1</sup>; <sup>1</sup>Children's Hospital Colorado, Aurora, CO, USA. <sup>2</sup>University of Colorado, Aurora, CO, USA

Despite a growing understanding and stratification of medulloblastoma, it remains an aggressive childhood brain tumor with high morbidity and mortality. Multimodal genomic and epigenomic analysis has permitted the classification of medulloblastoma into four subgroups with varying biology and clinical behavior: WNT, Sonic-Hedgehog (SHH), Group 3, and Group 4. In our previously published work, Single-cell RNA sequencing (scRNAseq) identified distinct tumor cell subpopulations in specific medulloblastoma groups. However, this technology is limited by its lack of architectural information. Spatial transcriptomics is a relatively new technology that permits the analysis of gene expression as it occurs within organized tissue. In our ongoing study, we utilized Visium spatial transcriptomics, integrated with scRNAseq data and immunohistochemistry, to analyze frozen samples of medulloblastomas (SHH, Group 4, and Group 3 with and without MYC amplification). In SHH in particular, we were able to identify scRNAseq